re: AUPH - Aurinia Pharmaceuticals

quote:

---

It seems this thing moves on good news then settles back down over time. Is it not still 12+ months away from any material breakthroughs driving revenue?

---

Nothing has driven this rise to $6 but a return to normalcy after a tax driven sell off that started in November.

You gotta figure that "normal" for this stock is $6.50 to $7 due to the massive number of shares that were offered last April at $6.75, which at the time, seemed like a GREAT deal.
The only reason it dropped much lower than that (into the $5s) is because they announced that phase III wouldn't be completed until late 2019. People dumped, and then people who bought at $7,8,9,10 dumped to harvest a tax loss late in 2017.

As predicted, it's rising back to a reasonable price that correlates to a 500-600 million market cap, and it's doing it faster than I expected.

Always remember, the potential sales for Voclosporin is upwards of 3 billion dollars. A buyout would likely reflect that price plus a little extra. Not likely to happen in 2018 though.